205 related articles for article (PubMed ID: 1283893)
1. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
Geller J; Sionit L
J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893
[TBL] [Abstract][Full Text] [Related]
2. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
4. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
5. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate.
Rittmaster RS; Magor KE; Manning AP; Norman RW; Lazier CB
Mol Endocrinol; 1991 Jul; 5(7):1023-9. PubMed ID: 1719382
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM
Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846
[TBL] [Abstract][Full Text] [Related]
9. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
10. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.
Brooks JR; Berman C; Nguyen H; Prahalada S; Primka RL; Rasmusson GH; Slater EE
Prostate; 1991; 18(3):215-27. PubMed ID: 1850515
[TBL] [Abstract][Full Text] [Related]
11. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat.
di Salle E; Giudici D; Biagini L; Cominato C; Briatico G; Panzeri A
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):381-5. PubMed ID: 7626485
[TBL] [Abstract][Full Text] [Related]
12. Finasteride for benign prostatic hyperplasia.
Hasinski S; Miller JL; Rose LI
Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
[TBL] [Abstract][Full Text] [Related]
13. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
14. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
[TBL] [Abstract][Full Text] [Related]
16. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
[TBL] [Abstract][Full Text] [Related]
17. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat.
George FW; Johnson L; Wilson JD
Endocrinology; 1989 Nov; 125(5):2434-8. PubMed ID: 2551651
[TBL] [Abstract][Full Text] [Related]
18. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
19. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
20. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
